Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,441 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,441 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02923986 | Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With… | Phase 1 / Phase 2 | withdrawn | Oct 5, 2016 | Bio-Path Holdings, Inc. | No enrollment | Enrollment / accrual |
| NCT03071276 | Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or… | Phase 2 | terminated | Mar 6, 2017 | St. Jude Children's Research Hospital | Due to slow enrollment | Enrollment / accrual |
| NCT02038153 | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone… | Phase 1 / Phase 2 | terminated | Jan 16, 2014 | Albert Einstein College of Medicine | Low accrual | Enrollment / accrual |
| NCT00303719 | Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy | Phase 2 | terminated | Mar 17, 2006 | Masonic Cancer Center, University of Minnesota | IRB Study Closure | Other (stated, no rule matched) |
| NCT02906696 | Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After… | Phase 2 | terminated | Sep 20, 2016 | M.D. Anderson Cancer Center | Terminated per PI's request due to competing priorities. | Other (stated, no rule matched) |
| NCT02535364 | Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic…(ROCKET) | Phase 2 | terminated | Aug 28, 2015 | Juno Therapeutics, a Subsidiary of Celgene | Safety reasons | Safety / toxicity |
| NCT03436771 | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | — | terminated | Feb 19, 2018 | Juno Therapeutics, a Subsidiary of Celgene | Eligible subjects will be enrolled in Celgene's long-term follow-up protocol for subjects… | Enrollment / accrual |
| NCT00513747 | Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated… | Phase 3 | terminated | Aug 9, 2007 | Alliance for Clinical Trials in Oncology | Insufficient accrual | Enrollment / accrual |
| NCT01636609 | Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute… | Phase 1 | terminated | Jul 10, 2012 | M.D. Anderson Cancer Center | In 2013 the FDA put a temporary hold on the trial and the Phase II portion of this study was… | Other (stated, no rule matched) |
| NCT00041288 | Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And… | Phase 2 | terminated | Jan 27, 2003 | University of Texas Southwestern Medical Center | Poor accrual and difficulty with multicenter logistics | Enrollment / accrual |
| NCT04100330 | A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory…(CyFi2) | Phase 2 | withdrawn | Sep 24, 2019 | AVEO Pharmaceuticals, Inc. | Urgent shift among clinical sites toward efforts to combat COVID-19 pandemic;impacted feasibility… | COVID-19 / pandemic |
| NCT00207831 | Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy…(UFT RT Phase 3) | Phase 3 | terminated | Sep 21, 2005 | Institut Cancerologie de l'Ouest | Terminated after interim analysis | Efficacy / futility |
| NCT02109627 | Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML | Phase 1 | terminated | Apr 10, 2014 | C. Babis Andreadis | Low Accrual | Enrollment / accrual |
| NCT02349178 | Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT | Phase 2 | terminated | Jan 28, 2015 | Medical College of Wisconsin | Low accrual | Enrollment / accrual |
| NCT03135028 | Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese…(Japanese AML) | Phase 1 | terminated | May 1, 2017 | Gilead Sciences | No signal of efficacy with Entospletinib | Efficacy / futility |
| NCT02875093 | Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML | Phase 1 | terminated | Aug 23, 2016 | Polaris Group | Study Termination | Other (stated, no rule matched) |
| NCT02341495 | Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML…(EXJADE) | Phase 2 | terminated | Jan 19, 2015 | Elizabeth Henry | Study was terminated early due to low patient accrual. | Enrollment / accrual |
| NCT02588092 | Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid… | Phase 1 | terminated | Oct 27, 2015 | ADC Therapeutics S.A. | Slow enrollment | Enrollment / accrual |
| NCT03281746 | Effect of Prevention Education in Caries Formation in Pediatric Patients With Leukemia | N/A | terminated | Sep 13, 2017 | Virginia Commonwealth University | Slow accrual | Enrollment / accrual |
| NCT01629511 | Allogeneic Stem Cell Transplant for CLL | Phase 1 / Phase 2 | terminated | Jun 27, 2012 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00939653 | T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia… | Phase 2 | terminated | Jul 15, 2009 | Therapeutic Advances in Childhood Leukemia Consortium | Due to insufficient research institution participation and patient enrollment | Enrollment / accrual |
| NCT00539656 | Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers(Cord Blood) | Phase 1 / Phase 2 | terminated | Oct 4, 2007 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The manufacturer discontinued necessary reagents. | Drug supply |
| NCT02225574 | An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in… | Phase 1 | terminated | Aug 26, 2014 | M.D. Anderson Cancer Center | Slow Accrual - Only 1 patient enrolled in Phase 1 - Study never went to Phase II | Enrollment / accrual |
| NCT02819804 | Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia… | Phase 1 | terminated | Jun 30, 2016 | Northwestern University | Due to funding and accrual issues | Enrollment / accrual |
| NCT01010256 | The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic… | — | terminated | Nov 9, 2009 | University of Arkansas | PI moved institutions | Other (stated, no rule matched) |
| NCT04043845 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | Phase 1 | withdrawn | Aug 2, 2019 | Dana-Farber Cancer Institute | Business development reasons. | Sponsor / business decision |
| NCT00899431 | Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) | Phase 2 | terminated | May 12, 2009 | M.D. Anderson Cancer Center | Terminated per PI's request at the time of continuing review | Other (stated, no rule matched) |
| NCT02370888 | Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia…(UF-BMT-MRD-101) | Phase 1 | terminated | Feb 25, 2015 | University of Florida | Slow accrual | Enrollment / accrual |
| NCT01887587 | Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia… | Phase 1 | terminated | Jun 27, 2013 | Ehab L Atallah | SAE- risk of overall protocol treatment outweighs benefits | Other (stated, no rule matched) |
| NCT02274506 | Infusion of Allogeneic, 3rd Party CD19-specific T Cells | Phase 1 | withdrawn | Oct 24, 2014 | M.D. Anderson Cancer Center | PI's response to ePAAC, has withdrawn the protocol acknowledging the PI's action. | Other (stated, no rule matched) |
| NCT02599649 | Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes… | Phase 2 | terminated | Nov 6, 2015 | M.D. Anderson Cancer Center | Enrollment was stopped after the sponsor's decision not to pursue the development of lirilumab for… | Enrollment / accrual |
| NCT02226497 | Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic… | N/A | terminated | Aug 27, 2014 | Fred Hutchinson Cancer Center | Insufficient staff | Other (stated, no rule matched) |
| NCT03760445 | HDM201 Added to CT in R/R or Newly Diagnosed AML | Phase 1 / Phase 2 | withdrawn | Nov 30, 2018 | Novartis Pharmaceuticals | It was determined that the study design may not be optimal given the changing AML treatment… | Other (stated, no rule matched) |
| NCT00006451 | Bone Marrow Transplantation in Treating Patients With Leukemia | Phase 3 | withdrawn | Jun 9, 2004 | Masonic Cancer Center, University of Minnesota | Terminated (due to no accrual) | Enrollment / accrual |
| NCT02010645 | Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) | Phase 2 | terminated | Dec 13, 2013 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT02404220 | Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With… | Phase 1 / Phase 2 | terminated | Mar 31, 2015 | Gilead Sciences | not stated | Not stated |
| NCT02145039 | Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With… | N/A | terminated | May 22, 2014 | Masonic Cancer Center, University of Minnesota | Replaced by another study. | Other (stated, no rule matched) |
| NCT02435550 | iCare for Cancer Patients | N/A | terminated | May 6, 2015 | University of Florida | Halted due to funding issues. | Funding |
| NCT02976558 | The Influence of TaKeTiNa Music Therapy, Traditional Chinese Acupuncture and Clown…(TriCAM) | N/A | terminated | Nov 29, 2016 | University of Erlangen-Nürnberg Medical School | Due to organisational issues, the study had to be completed prematurely. | Other (stated, no rule matched) |
| NCT00973804 | Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched… | Phase 1 | terminated | Sep 9, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02231853 | Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells… | Phase 1 | terminated | Sep 4, 2014 | National Heart, Lung, and Blood Institute (NHLBI) | not stated | Not stated |
| NCT02557516 | Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or… | Phase 1 / Phase 2 | terminated | Sep 23, 2015 | Innate Pharma | Sponsor decision | Sponsor / business decision |
| NCT00022971 | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia | Phase 1 | terminated | Aug 20, 2001 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02160795 | Feasibility of Identifying a Chinese Study Population and Eligible Pediatric Cancer… | — | withdrawn | Jun 11, 2014 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00582816 | Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid… | Phase 1 / Phase 2 | terminated | Dec 28, 2007 | University of Wisconsin, Madison | toxicity | Safety / toxicity |
| NCT02174445 | An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of…(DECLINE) | Phase 3 | terminated | Jun 25, 2014 | Prof. Dr. Nikolas von Bubnoff | very slow recruitment rate and a lot of pat. didn't fulfil BCR-ABL requirements | Enrollment / accrual |
| NCT00085449 | Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate… | Phase 1 / Phase 2 | withdrawn | Jun 11, 2004 | Alliance for Clinical Trials in Oncology | Funding cut, no patients enrolled | Enrollment / accrual |
| NCT02954653 | A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In… | Phase 1 | terminated | Nov 3, 2016 | Pfizer | The study was terminated due to a change in sponsor prioritization. | Other (stated, no rule matched) |
| NCT03483948 | Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia | Phase 1 | terminated | Mar 30, 2018 | Hutchison Medipharma Limited | Slow Enrollment | Enrollment / accrual |
| NCT00117845 | Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin… | Phase 2 | terminated | Jul 8, 2005 | National Cancer Institute (NCI) | Premature closure as study drug is no longer available from the manufacturer. | Drug supply |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 28, 2020source: clinicaltrials